| MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling JA Engelman, K Zejnullahu, T Mitsudomi, Y Song, C Hyland, JO Park, ... science 316 (5827), 1039-1043, 2007 | 5466 | 2007 |
| First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer BJ Solomon, T Mok, DW Kim, YL Wu, K Nakagawa, T Mekhail, E Felip, ... New England Journal of Medicine 371 (23), 2167-2177, 2014 | 3618 | 2014 |
| Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC MA Socinski, RM Jotte, F Cappuzzo, F Orlandi, D Stroyakovskiy, ... New England Journal of Medicine 378 (24), 2288-2301, 2018 | 3447 | 2018 |
| Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective … W De Roock, B Claes, D Bernasconi, J De Schutter, B Biesmans, ... The lancet oncology 11 (8), 753-762, 2010 | 2574 | 2010 |
| First-line nivolumab in stage IV or recurrent non–small-cell lung cancer DP Carbone, M Reck, L Paz-Ares, B Creelan, L Horn, M Steins, E Felip, ... New England Journal of Medicine 376 (25), 2415-2426, 2017 | 2538 | 2017 |
| Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non–small-cell lung cancer F Cappuzzo, FR Hirsch, E Rossi, S Bartolini, GL Ceresoli, L Bemis, ... Journal of the National Cancer Institute 97 (9), 643-655, 2005 | 1962 | 2005 |
| Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase … NA Rizvi, J Mazières, D Planchard, TE Stinchcombe, GK Dy, SJ Antonia, ... The lancet oncology 16 (3), 257-265, 2015 | 1674 | 2015 |
| Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study F Cappuzzo, T Ciuleanu, L Stelmakh, S Cicenas, A Szczésna, E Juhász, ... The lancet oncology 11 (6), 521-529, 2010 | 1599 | 2010 |
| Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer M Peifer, L Fernández-Cuesta, ML Sos, J George, D Seidel, LH Kasper, ... Nature genetics 44 (10), 1104-1110, 2012 | 1487 | 2012 |
| Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy … EB Garon, TE Ciuleanu, O Arrieta, K Prabhash, KN Syrigos, T Goksel, ... The Lancet 384 (9944), 665-673, 2014 | 1414 | 2014 |
| Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small … H West, M McCleod, M Hussein, A Morabito, A Rittmeyer, HJ Conter, ... The Lancet Oncology 20 (7), 924-937, 2019 | 1410 | 2019 |
| Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer J Weiss, ML Sos, D Seidel, M Peifer, T Zander, JM Heuckmann, RT Ullrich, ... Science translational medicine 2 (62), 62ra93-62ra93, 2010 | 1008 | 2010 |
| Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in … M Reck, TSK Mok, M Nishio, RM Jotte, F Cappuzzo, F Orlandi, ... The Lancet Respiratory Medicine 7 (5), 387-401, 2019 | 872 | 2019 |
| Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab K Yonesaka, K Zejnullahu, I Okamoto, T Satoh, F Cappuzzo, J Souglakos, ... Science translational medicine 3 (99), 99ra86-99ra86, 2011 | 711 | 2011 |
| PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients A D'incecco, M Andreozzi, V Ludovini, E Rossi, A Capodanno, L Landi, ... British journal of cancer 112 (1), 95-102, 2015 | 651 | 2015 |
| Increased MET Gene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer Patients F Cappuzzo, A Marchetti, M Skokan, E Rossi, S Gajapathy, L Felicioni, ... Journal of clinical oncology 27 (10), 1667-1674, 2009 | 625 | 2009 |
| Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer KD Davies, AT Le, MF Theodoro, MC Skokan, DL Aisner, EM Berge, ... Clinical Cancer Research 18 (17), 4570-4579, 2012 | 536 | 2012 |
| Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized phase III trial R Jotte, F Cappuzzo, I Vynnychenko, D Stroyakovskiy, ... Journal of Thoracic Oncology 15 (8), 1351-1360, 2020 | 477 | 2020 |
| Increased HER2 Gene Copy Number Is Associated With Response to Gefitinib Therapy in Epidermal Growth Factor Receptor–Positive Non–Small-Cell Lung … F Cappuzzo, M Varella-Garcia, H Shigematsu, I Domenichini, S Bartolini, ... Journal of clinical oncology 23 (22), 5007-5018, 2005 | 466 | 2005 |
| Akt phosphorylation and gefitinib efficacy in patients with advanced non–small-cell lung cancer F Cappuzzo, E Magrini, GL Ceresoli, S Bartolini, E Rossi, V Ludovini, ... Journal of the National Cancer Institute 96 (15), 1133-1141, 2004 | 453 | 2004 |
Romano DanesiProfessor of Pharmacology, University of MilanoEmail verificata su unimi.it
